Summer 2010

Ten Questions Every Patient Should be Asking

More and more deadly diseases are slowly being transformed into chronic conditions. This is especially true of cancer.

By now, I am supposed to be dead.

The Prostate Cancer Clinical States model was first proposed by Scher and colleagues nearly 10 years ago.

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.

Androgen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.

FDA updates from the summer of 2010

The FDA approved Tasigna (nilotinib) as a first-line treatment for patients with newly diagnosed Philadelphia- chromosome positive (Ph ) chronic myeloid leukemia (CML), the first new drug approved for this indication in nearly a decade.

The FDA approved the injectable drug Jevtana (cabazitaxel), a microtubule inhibitor, in combination with prednisone as a second-line therapy for men with advanced castrate-resistant prostate cancer

In the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) phase III study involving patients with pancreatic neuroendocrine tumors (NET)

As 2010 has rolled along, the Intellisphere Oncology Specialty Group has aimed to uphold its mission of Bringing the Oncology Community Together.

The landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease